Skip to main content

Table 7 Number (%) of patients reporting an adverse event, safety population

From: Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study

Category of AE n = 60
Any adverse events (AEs) 60 (100)
Treatment-related AEs  
   Possibly treatment-related 32 (53.3)
   Probably treatment-related 16 (26.7)
   Definitely treatment-related 0 (0)
Serious AEs 2 (3.3)
   Serious treatment-related AEs a 0 (0)
Discontinuations due to AEs b 12 (20.0)
   Treatment-related discontinuations due to AE a 10 (16.7)
  1. a Number (%) of patients with an AE assessed as possibly, probably or definitely related to study medication
  2. b The AE case report form (CRF) page captured information regarding whether a patient withdrew from the study as a result of an AE. The End of Study CRF page captured withdrawal information and stated that a patient withdrew due to an AE, although this was not recorded as a withdrawal as a result of an AE on the AE CRF page